Search

Your search keyword '"Borsellino, Nicolò"' showing total 40 results
Start Over Author "Borsellino, Nicolò"
40 results on '"Borsellino, Nicolò"'

5. Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

Author

Facchini, Gaetano, Rossetti, Sabrina, Berretta, Massimiliano, Cavaliere, Carla, Scagliarini, Sarah, Vitale, Maria Giuseppa, Ciccarese, Chiara, Di Lorenzo, Giuseppe, Palesandro, Erica, Conteduca, Vincenza, Basso, Umberto, Naglieri, Emanuele, Farnesi, Azzurra, Aieta, Michele, Borsellino, Nicolò, La Torre, Leonardo, Iovane, Gelsomina, Bonomi, Lucia, Gasparro, Donatello, Ricevuto, Enrico, De Tursi, Michele, De Vivo, Rocco, Lo Re, Giovanni, Grillone, Francesco, Marchetti, Paolo, De Vita, Ferdinando, Scavelli, Claudio, Sini, Claudio, Pisconti, Salvatore, Crispo, Anna, Gebbia, Vittorio, Maestri, Antonio, Galli, Luca, De Giorgi, Ugo, Iacovelli, Roberto, Buonerba, Carlo, Cartenì, Giacomo, and D’Aniello, Carmine

Published
2019
Full Text
View/download PDF

7. Feasibility of cabazitaxel in octogenarian prostate cancer patients

Author

Tralongo, Paolo, primary, Bordonaro, Sebastiano, additional, Di Lorenzo, Giuseppe, additional, De Giorgi, Ugo, additional, Borsellino, Nicolò, additional, Facchini, Gaetano, additional, Rossetti, Sabrina, additional, Fornarini, Giuseppe, additional, Longo, Vito, additional, Tralongo, Antonino Carmelo, additional, Caspani, Francesca, additional, Spada, Massimiliano, additional, Calvani, Nicola, additional, and Carlini, Paolo, additional

Published
2022
Full Text
View/download PDF

8. Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide

Author

La Vecchia, Maria, Fazio, Ivan, Borsellino, Nicolò, Lo Casto, Antonio, and Galanti, Daniele

Abstract

Introduction: This monocentric, single-arm, retrospective study investigated the role of stereotactic body radiotherapy in patients with metastatic castration resistant prostate cancer who experienced oligoprogression during androgen receptor targeted agents.Methods: We retrospectively enrolled metastatic castration resistant prostate cancer patients treated with androgen receptor targeted agents between December 2016 and January 2022. All patients experienced an oligoprogression (defined as the appearance and/or the progression of ⩽5 bone or nodal or soft tissue metastases) during treatment with androgen receptor targeted agents and received stereotactic body radiotherapy upon oligoprogressive sites, preserving the androgen receptor targeted agents. Further stereotactic body radiotherapy upon new metastatic sites was permitted. Patients showing visceral metastases or receiving palliative radiotherapy were excluded. Progressive disease at >5 metastatic sites or the appearance of visceral metastases led to a change of the systemic treatment. Primary endpoints were 36-month survival rate and 36-month rate of patients receiving treatment with androgen receptor targeted agents. Secondary endpoints were local disease control, biochemical response and safety.Results: We analyzed data from 30 patients. The 36-month survival rate was 90% (27 patients); 36-month rate of patients who were still on treatment with androgen receptor targeted agents was 50%. 20 of 30 patients had performed imaging control after a single course of stereotactic body radiotherapy: overall response rate was 50%, while clinical benefit was 93%. No ⩾G2 adverse events related to stereotactic body radiotherapy were recorded.Conclusions: Stereotactic body radiotherapy in oligoprogressive metastatic sites during androgen receptor targeted agent treatment resulted in a feasible and effective treatment to delay the start of next-line systemic treatment and prolong overall survival in metastatic castration resistant prostate cancer. Longer follow-up and further prospective studies are necessary to confirm our preliminary results.

Published
2023
Full Text
View/download PDF

14. Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World

Author

GEBBIA, VITTORIO, primary, GIRLANDO, ANDREA, additional, DI GRAZIA, ALFIO, additional, FAZIO, IVAN, additional, BORSELLINO, NICOLÒ, additional, PIAZZA, DARIO, additional, SERRETTA, VINCENZO, additional, PERGOLIZZI, STEFANO, additional, PONTORIERO, ANTONIO, additional, FIRENZE, ALBERTO, additional, and VALERIO, MARIA ROSARIA, additional

Published
2020
Full Text
View/download PDF

16. Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis

Author

Gebbia, Vittorio, primary, Aiello, Marco Maria, additional, Banna, Giuseppe, additional, Blanco, Giusi, additional, Blasi, Livio, additional, Borsellino, Nicolò, additional, Giuffrida, Dariio, additional, Lo Mauro, Mario, additional, Mancuso, Gianfranco, additional, Piazza, Dario, additional, Savio, Giuseppina, additional, Soto Parra, Hector, additional, Valerio, Maria Rosaria, additional, Verderame, Francesco, additional, and Vigneri, Paolo, additional

Published
2020
Full Text
View/download PDF

20. Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: a WhatsApp messenger-based report from the Italian College of Chief Medical Oncologists

Author

Blasi, Livio, primary, Bordonaro, Roberto, additional, Borsellino, Nicolò, additional, Butera, Alfredo, additional, Caruso, Michele, additional, Cordio, Stefano, additional, Liborio, Di Cristina, additional, Ferraù, Francesco, additional, Giuffrida, Dario, additional, Soto Parra, Hector, additional, Spada, Massimiliano, additional, Tralongo, Paolo, additional, Valenza, Roberto, additional, Verderame, Francesco, additional, Vitello, Stefano, additional, Zerilli, Filippo, additional, Piazza, Dario, additional, Firenze, Alberto, additional, and Gebbia, Vittorio, additional

Published
2020
Full Text
View/download PDF

21. Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?

Author

Serretta, Vincenzo, primary, Valerio, Maria Rosaria, additional, Costa, Renato, additional, Tripoli, Vincenzo, additional, Murabito, Alessandra, additional, Princiotta, Alessandro, additional, Scalici Gesolfo, Cristina, additional, Borsellino, Nicolò, additional, Verderame, Francesco, additional, Gebbia, Vittorio, additional, Licari, Maria, additional, and Sanfilippo, Chiara, additional

Published
2019
Full Text
View/download PDF

24. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB–IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale

Author

Gebbia, Vittorio, Galetta, Domenico, Caruso, Michele, Verderame, Francesco, Pezzella, Giuseppe, Valdesi, Matteo, Borsellino, Nicolò, Pandolfo, Giuseppe, Durini, Ernesto, Rinaldi, Massimo, Loizzi, Michele, Gebbia, Nicola, Valenza, Roberto, Tirrito, Maria Lina, Varvara, Francesca, and Colucci, Giuseppe

Published
2003
Full Text
View/download PDF

25. NEPA as antiemetic prophylaxis after failure of 5HT3-RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience.

Author

Valerio, Maria Rosaria, Gebbia, Vittorio, Borsellino, Nicolò, Vecchia, Maria La, Serretta, Vincenzo, Pardo, Salvatore, Cipolla, Calogero, and Galanti, Daniele

Subjects
DRUG efficacy, SAFETY, LUNG cancer, BLADDER tumors, COMBINATION drug therapy, CARBOPLATIN, OVARIAN tumors, DRUG tolerance, SEROTONIN antagonists, DEXAMETHASONE, CANCER chemotherapy, ISOQUINOLINE, ANTINEOPLASTIC agents, METASTASIS, TREATMENT effectiveness, CANCER patients, ANTIMETABOLITES, EXPERIENCE, DESCRIPTIVE statistics, ONDANSETRON, ANTIEMETICS, EVALUATION
Abstract

Introduction: Chemotherapy-induced nausea and vomiting (CINV) may affect adherence to planned chemotherapy treatments and compromise patients' quality of life during the therapy. NEPA is an oral fixed combination of netupitant, a highly-selective NK1-RA and palonosetron, a 5HT3-RA, approved for the prevention of acute and delayed CINV. The aim of this study was to evaluate the efficacy and safety of NEPA with dexamethasone for CINV prophylaxis in the challenging setting of carboplatin and gemcitabine combination chemotherapy, after failure of prophylaxis with 5HT3 receptor antagonist. Methods: Eligible patients were undergoing carboplatin and gemcitabine combination chemotherapy for metastatic non-small cell lung cancer (NSCLC), ovarian cancer or urothelial cancer and experienced nausea and/or vomiting after the first cycle of chemotherapy, despite an antiemetic prophylaxis with a 5HT3-RA and dexamethasone. Primary efficacy endpoint was complete response (CR: no emesis, no rescue medication) obtained with NEPA, during the overall phase (0–120 h), after the start of chemotherapy. Results: During the first cycle of chemotherapy, 15 out of 30 (50%) patients did not properly control CINV with a 5HT3-RA plus dexamethasone used as primary antiemetic prophylaxis and then were switched to NEPA from the subsequent cycle. During NEPA administration, 13 out of 15 patients (86.7%) achieved an overall CR (no emesis, no rescue medication). Antiemetic treatment with NEPA was very well tolerated with only two patients (13.3%) that experienced a grade 1 TEAE. Conclusions: Our experience showed that NEPA has proven to be very effective and well tolerated in the prophylaxis of CINV induced by carboplatin-based chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

28. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: A quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale

Author

Gebbia, Vittorio, primary, Lorusso, Vito, additional, Galetta, Domenico, additional, Caruso M, Michele, additional, Palomba, Giuseppe, additional, Riccardi, Fernando, additional, Borsellino, Nicolò, additional, Carrozza, Francesco, additional, Leo, Silvana, additional, Ferraù, Francesco, additional, Cinieri, Saverio, additional, Mancuso, Gianfranco, additional, Mancarella, Sergio, additional, and Colucci, Giuseppe, additional

Published
2010
Full Text
View/download PDF

29. Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I–II study

Author

Gebbia, Vittorio, primary, Di Marco, Pietro, additional, Borsellino, Nicolò, additional, Gebbia, Nicolò, additional, Valerio, Maria Rosaria, additional, Fallica, Giuseppina, additional, Tirrito, Maria Lina, additional, Valenza, Roberto, additional, Citarrella, Pietro, additional, and Panici, Pierluigi Benedetti, additional

Published
2003
Full Text
View/download PDF

33. Methotrexate, Vinblastine, Epidoxorubicin, and Bleomycin as Second-Line Chemotherapy for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Author

Gebbia, Vittorio, primary, Valenza, Roberto, additional, Testa, Antonio, additional, Borsellino, Nicolò, additional, Cannata, Giuseppe, additional, Restivo, Salvatore, additional, Speciale, Riccardo, additional, Ingria, Federico, additional, Spadafora, Giovanni, additional, and Gebbia, Nicola, additional

Published
1994
Full Text
View/download PDF

37. Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide

Author

Maria La Vecchia, Ivan Fazio, Nicolò Borsellino, Antonio Lo Casto, Daniele Galanti, La Vecchia, Maria, Fazio, Ivan, Borsellino, Nicolò, Galanti, Daniele, and Lo Casto, Antonio

Subjects
Cancer Research, enzalutamide, Oncology, Stereotactic body radiotherapy, abiraterone, metastatic castration resistant prostate cancer, General Medicine, oligometastatic disease, Settore MED/36 - Diagnostica Per Immagini E Radioterapia
Abstract

Introduction: This monocentric, single-arm, retrospective study investigated the role of stereotactic body radiotherapy in patients with metastatic castration resistant prostate cancer who experienced oligoprogression during androgen receptor targeted agents. Methods: We retrospectively enrolled metastatic castration resistant prostate cancer patients treated with androgen receptor targeted agents between December 2016 and January 2022. All patients experienced an oligoprogression (defined as the appearance and/or the progression of ⩽5 bone or nodal or soft tissue metastases) during treatment with androgen receptor targeted agents and received stereotactic body radiotherapy upon oligoprogressive sites, preserving the androgen receptor targeted agents. Further stereotactic body radiotherapy upon new metastatic sites was permitted. Patients showing visceral metastases or receiving palliative radiotherapy were excluded. Progressive disease at >5 metastatic sites or the appearance of visceral metastases led to a change of the systemic treatment. Primary endpoints were 36-month survival rate and 36-month rate of patients receiving treatment with androgen receptor targeted agents. Secondary endpoints were local disease control, biochemical response and safety. Results: We analyzed data from 30 patients. The 36-month survival rate was 90% (27 patients); 36-month rate of patients who were still on treatment with androgen receptor targeted agents was 50%. 20 of 30 patients had performed imaging control after a single course of stereotactic body radiotherapy: overall response rate was 50%, while clinical benefit was 93%. No ⩾G2 adverse events related to stereotactic body radiotherapy were recorded. Conclusions: Stereotactic body radiotherapy in oligoprogressive metastatic sites during androgen receptor targeted agent treatment resulted in a feasible and effective treatment to delay the start of next-line systemic treatment and prolong overall survival in metastatic castration resistant prostate cancer. Longer follow-up and further prospective studies are necessary to confirm our preliminary results.

Published
2022

38. Patients With Cancer and COVID-19: A WhatsApp Messenger-Based Survey of Patients' Queries, Needs, Fears, and Actions Taken

Author

Alberto Firenze, Nicolò Borsellino, Vittorio Gebbia, Maria Rosaria Valerio, Dario Piazza, Gebbia, Vittorio, Piazza, Dario, Valerio, Maria Rosaria, Borsellino, Nicolò, and Firenze, Alberto

Subjects
0301 basic medicine, Cancer Research, 2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), WhatsApp messenger, cancer patient, reactions, action taken, COVID-19 outbreak, sentimental analysis, Pneumonia, Viral, MEDLINE, Time to treatment, Time-to-Treatment, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Surveys and Questionnaires, Original Reports, Pandemic, medicine, Humans, Intensive care medicine, Pandemics, Text Messaging, business.industry, COVID-19, Cancer, Fear, medicine.disease, Pneumonia, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Coronavirus Infections, business
Abstract

PURPOSE This descriptive investigation was undertaken at three oncology units to report queries, needs, and fears related to severe acute respiratory syndrome coronavirus 2 (COVID-19) of patients with cancer and to avoid uncontrolled treatment delays or withdrawal, behavioral mistakes, and panic. PATIENTS AND METHODS All queries spontaneously delivered through the WhatsApp instant messaging system commonly used by patients to communicate with oncology units were collected and grouped by homology in five categories. Responses to the queries were given according to recommendations by the Italian Association of Medical Oncology through WhatsApp and by subsequent phone calls. Patients were also classified according to the site of the primary tumor, stage of disease, and current treatments. Analysis of the association between these data and queries was carried out. RESULTS The social scenario in Italy is a nationwide lockdown except for hospitals, pharmacies, and food supplies. Overall, 446 different patients’ WhatsApp conversations were analyzed between March 1 and March 13 and comprised the following: requirement of visit delay by patients undergoing oral therapies or in follow-up, delays in chemotherapy or immunotherapy administration, queries about possible immunosuppression, and changes in lifestyle or daily activities. Delay requirements were statistically more frequent among patients with prostate or breast cancer compared with those with lung or pancreatic cancer. Actions taken by oncologists are also reported. CONCLUSION To our knowledge, the WhatsApp instant messaging system has been occasionally used in other medical settings with controversial results. In our experience, WhatsApp turned out to be adequate to give a rapid answer to most queries from patients with cancer in the COVID-19 pandemic scenario.

Published
2020

39. Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis

Author

Paolo Vigneri, Giuseppe Luigi Banna, Dariio Giuffrida, Maria Rosaria Valerio, Nicolò Borsellino, Vittorio Gebbia, Dario Piazza, Mario Lo Mauro, Hector Soto Parra, Gianfranco Mancuso, Giusi Blanco, Francesco Verderame, Livio Blasi, Giuseppina Savio, Marco Aiello, Gebbia, Vittorio, Aiello, Marco Maria, Banna, Giuseppe, Blanco, Giusi, Blasi, Livio, Borsellino, Nicolò, Giuffrida, Dario, Mauro, Mario Lo, Mancuso, Gianfranco, Piazza, Dario, Savio, Giuseppina, Parra, Hector Soto, Valerio, Maria Rosaria, Verderame, Francesco, and Vigneri, Paolo

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Disease, Vinorelbine, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, Lung cancer, Survival rate, non-small cell lung cancer, nivolumab, Chemotherapy, business.industry, Immunotherapy, medicine.disease, metronomic therapy, 030104 developmental biology, 030220 oncology & carcinogenesis, Clinical Study, oral vinorelbine, Nivolumab, business, Progressive disease, medicine.drug
Abstract

Purpose The availability of immune checkpoint inhibitors has deeply changed the therapeutic scenario of patients with advanced non-small cell lung cancer (NSCLC). Up until now, chemotherapy still represents the first-line treatment for patients with advanced NSCLC not harbouring genetic mutations or lacking high expression of programmed death ligand even if the addition of immunotherapy to first-line chemotherapy has recently been shown to improve clinical outcome. We carried out a multi-institutional retrospective analysis on third-line chemotherapy with metronomic oral vinorelbine (VNR) in a series of patients with metastatic NSCLC pre-treated with first-line chemotherapy and second-line immunotherapy. Patients and methods Thirty patients with metastatic NSCLC with progressive disease after first-line chemotherapy and subsequent immunotherapy were treated with metronomic oral VNR continuously at the fixed dose of 30 mg three times per week. Results A partial response was achieved in 4 patients (13.3%), while 10 patients (33.3%) displayed disease stabilisation for an overall disease control rate of 46.7%. Median progression-free survival was 3.9 months (range 1-13 months) and median OS reached 8.1 months (range 4.0-24.0+ months) with a 12-month survival rate of 22%. Conclusion Oral metronomic VNR appears to be active and safe in patients with metastatic NSCLC in progression after first-line chemotherapy and second-line immunotherapy. The results reported, although from a limited sample, may suggest its use for long-term stabilisation of the disease with good patient compliance.

Published
2020

40. NEPA as antiemetic prophylaxis after failure of 5HT 3 -RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience.

Author

Valerio MR, Gebbia V, Borsellino N, Vecchia M, Serretta V, Pardo S, Cipolla C, and Galanti D

Subjects
Adult, Carboplatin administration & dosage, Carboplatin adverse effects, Deoxycytidine administration & dosage, Deoxycytidine adverse effects, Deoxycytidine analogs & derivatives, Female, Humans, Male, Middle Aged, Nausea chemically induced, Palonosetron administration & dosage, Pyridines administration & dosage, Retrospective Studies, Treatment Failure, Vomiting chemically induced, Gemcitabine, Antiemetics administration & dosage, Dexamethasone administration & dosage, Drug Therapy, Combination adverse effects, Nausea prevention & control, Pre-Exposure Prophylaxis methods, Serotonin 5-HT3 Receptor Antagonists administration & dosage, Vomiting prevention & control
Abstract

Introduction: Chemotherapy-induced nausea and vomiting (CINV) may affect adherence to planned chemotherapy treatments and compromise patients' quality of life during the therapy. NEPA is an oral fixed combination of netupitant, a highly-selective NK 1 -RA and palonosetron, a 5HT 3 -RA, approved for the prevention of acute and delayed CINV. The aim of this study was to evaluate the efficacy and safety of NEPA with dexamethasone for CINV prophylaxis in the challenging setting of carboplatin and gemcitabine combination chemotherapy, after failure of prophylaxis with 5HT3 receptor antagonist., Methods: Eligible patients were undergoing carboplatin and gemcitabine combination chemotherapy for metastatic non-small cell lung cancer (NSCLC), ovarian cancer or urothelial cancer and experienced nausea and/or vomiting after the first cycle of chemotherapy, despite an antiemetic prophylaxis with a 5HT 3 -RA and dexamethasone. Primary efficacy endpoint was complete response (CR: no emesis, no rescue medication) obtained with NEPA, during the overall phase (0-120 h), after the start of chemotherapy., Results: During the first cycle of chemotherapy, 15 out of 30 (50%) patients did not properly control CINV with a 5HT 3 -RA plus dexamethasone used as primary antiemetic prophylaxis and then were switched to NEPA from the subsequent cycle. During NEPA administration, 13 out of 15 patients (86.7%) achieved an overall CR (no emesis, no rescue medication). Antiemetic treatment with NEPA was very well tolerated with only two patients (13.3%) that experienced a grade 1 TEAE., Conclusions: Our experience showed that NEPA has proven to be very effective and well tolerated in the prophylaxis of CINV induced by carboplatin-based chemotherapy.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results